US 11820982
Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors
granted A61KA61K31/7105A61K38/465
Quick answer
US patent 11820982 (Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K31/7105, A61K38/465